The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).
 
Neeta Somaiah
Consulting or Advisory Role - Bayer; Deciphera; Immune Design
Research Funding - MedImmune
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Elizabeth Goodwin Hill
No Relationships to Disclose
 
Mohammed M. Milhem
Honoraria - Amgen; Blueprint Medicines; Immunocore; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Blueprint Medicines; Immunocore; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Scott Schuetze
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - AB Science (Inst); Adaptimmune (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); CytRx Corporation (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Blueprint Medicines
 
Christian Frederick Meyer
Consulting or Advisory Role - Eisai; Janssen
Travel, Accommodations, Expenses - Lilly; Plexxikon
Other Relationship - UpToDate
 
Daniel Y. Reuben
No Relationships to Disclose
 
Anthony D. Elias
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Agilent; Alexion Pharmaceuticals; Align Oncology; Allergan; Amgen; Biogen; Bristol-Myers Squibb; Celgene; Cigna; Gilead Sciences; Illumina; Lilly; Merck; Pfizer; United Health Group
Consulting or Advisory Role - HSIX
Research Funding - Astellas Pharma (Inst); CytRx Corporation (Inst); Eisai (Inst); Eisai (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Johnson & Johnson (Inst); Medivation (Inst)
 
William L. Read
No Relationships to Disclose
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Amy E. Wahlquist
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Consulting or Advisory Role - Deciphera; Okava Pharmaceuticals; Tactical Therapeutics; TYME
 
Andrew S. Kraft
No Relationships to Disclose